Detalhe da pesquisa
1.
Ribociclib plus Endocrine Therapy in Early Breast Cancer.
N Engl J Med
; 390(12): 1080-1091, 2024 Mar 21.
Artigo
Inglês
| MEDLINE | ID: mdl-38507751
2.
Shaping the future of biomarker research in breast cancer to ensure clinical relevance.
Nat Rev Cancer
; 7(4): 309-15, 2007 04.
Artigo
Inglês
| MEDLINE | ID: mdl-17384585
3.
Adjuvant trastuzumab in HER2-positive breast cancer.
N Engl J Med
; 365(14): 1273-83, 2011 Oct 06.
Artigo
Inglês
| MEDLINE | ID: mdl-21991949
4.
Cancer goal: Deadline will not erode trust.
Nature
; 493(7432): 304, 2013 Jan 17.
Artigo
Inglês
| MEDLINE | ID: mdl-23325197
5.
Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer.
Ther Adv Med Oncol
; 15: 17588359231178125, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-37275963
6.
Quantitative impact of including consumers in the scientific review of breast cancer research proposals.
J Womens Health Gend Based Med
; 11(4): 379-88, 2002 May.
Artigo
Inglês
| MEDLINE | ID: mdl-12150500
7.
Let the patient's voice be heard in health care research. Interview by Lisette Hilton.
Healthplan
; 44(3): 42-9, 2003.
Artigo
Inglês
| MEDLINE | ID: mdl-12808758